Objectives: Dietary phosphorus loading markedly affects fibroblast growth factor-23 (FGF-23), which is a key factor responsible for many of the cardiovascular disease (CVD) and death in early chronic kidney disease (CKD). This study aimed to examine the dietary phosphorus load in CKD patients according to their dietary phosphorous intake (DPhI) in CKD patients and to find the risk factors that might be associated with the progression of CKD (stage 1/2). Design and setting: This cross-sectional study was conducted in the nephrology and endocrinology departments of the institute. Participants: Seventy-nine CKD patients were included and based on their DPhI, all the patients were categorized into 2 groups: recommended phosphorous intake (RPhI) group (n=37) with <1000 mg/day and high phosphorous intake (HPhI) group (n=42) with >1000mg/day. Results: In HPhI group; low sKlotho and HDL levels and high serum phosphorous (SP), FGF-23 and cholesterol levels correlated significantly with high intake of dietary phosphorous. FGF-23, SP, dietary protein and total cholesterol levels were significantly higher and sKlotho and HDL levels were significantly lower in HPhI than RPhI group. Risk factors with a statistical bearing on the progression of CKD were animal-based diet, family history of CKD, hypertension, high cholesterol and low HDL levels. Conclusions: CKD patients should be examined and counselled on their first visit on the impact of dietary phosphorus intake responsible for the progression of CKD and the development of CVD. Restricting DPhI at early stages of CKD can be a probable therapeutic interventional strategy for preserving renal function in CKD patients. Keywords: chronic kidney disease; fibroblast growth factor-23; phosphorous, dietary phosphorus intake, risk factors